Bone Income Before Tax from 2010 to 2024

BBLGW Stock  USD 27.80  0.00  0.00%   
Bone Biologics Income Before Tax yearly trend continues to be fairly stable with very little volatility. Income Before Tax is likely to outpace its year average in 2024. During the period from 2010 to 2024, Bone Biologics Income Before Tax regression line of quarterly data had r-squared of  0.05 and coefficient of variation of (117.53). View All Fundamentals
 
Income Before Tax  
First Reported
2013-03-31
Previous Quarter
-783.7 K
Current Value
-941 K
Quarterly Volatility
1.9 M
 
Yuan Drop
 
Covid
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 9.9 M, Ebitda of 503.6 K or Total Operating Expenses of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
  
Check out the analysis of Bone Biologics Correlation against competitors.

Latest Bone Biologics' Income Before Tax Growth Pattern

Below is the plot of the Income Before Tax of Bone Biologics Corp over the last few years. Income Before Tax which can also be referred as pre-tax income is reported on Bone Biologics income statement and is an important metric when analyzing Bone Biologics Corp profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability. It is Bone Biologics' Income Before Tax historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
Income Before Tax10 Years Trend
Pretty Stable
   Income Before Tax   
       Timeline  

Bone Income Before Tax Regression Statistics

Arithmetic Mean(5,106,826)
Coefficient Of Variation(117.53)
Mean Deviation4,514,790
Median(3,423,208)
Standard Deviation6,001,940
Sample Variance36T
Range21M
R-Value(0.22)
Mean Square Error37T
R-Squared0.05
Significance0.44
Slope(291,672)
Total Sum of Squares504.3T

Bone Income Before Tax History

2024-8.5 M
2023-8.9 M
2022-1.5 M
2021-1.6 M
2020-1.8 M
2019-3.4 M
2018-4.4 M

About Bone Biologics Financial Statements

Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Income Before Tax, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Before Tax-8.9 M-8.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.